Aberrant FGF19/FGFR4 signaling pathways (i.e., amplification, mutation, rearrangements, or overexpression) have been detected in a variety of cancers, such as hepatocellular carcinoma (HCC), breast cancer, prostate cancer, and pancreatic cancer16. Here, FGF19 is linked to hepatocellular carcinoma.